Synthekine

Synthekine is proud to be chosen as one of this year's Fierce 15 winners! We are honored to be named as one of the most promising early-stage biotechnology companies in the industry. Thank you, Fierce Biotech, for recognizing the work of our amazing team and our mission to develop the next generation of #cytokine therapeutics. Learn more: https://lnkd.in/e85ZGXyY   #Fierce152022 #Fierce15 #Biotech

This week, Alex Azrilevich, Pharm.D., our Vice President, Clinical Development, will be presenting on the promising potential of STK-012, our first-in-class α/β-biased IL-2 partial agonist for the treatment of advanced solid tumors, at the Kidney Cancer Research Summit hosted by KidneyCAN. Learn more: https://bit.ly/45RjH3r #KCRS24 #KidneyCancer

Our Scientific Founder, K. Christopher Garcia, Ph.D., was recently awarded the 2024 Passano Award for his research on the structural and mechanistic biology of cell surface receptors and its implications for safer and more effective treatments. Dr. Garcia’s research is foundational in our efforts to develop novel therapeutics targeting cytokine signaling pathways. Join us in congratulating Dr. Garcia on this prestigious honor! Learn more: https://bit.ly/4bLMokL

Next week, our VP of Business Development, Kunal Patel, will be joining a panel titled “A Licensing Deal for All Seasons” to discuss best practices for partnerships at the BIO International Convention in San Diego, CA. Don’t miss this opportunity to hear strategic insights for navigating #biotech partnerships from experts in the industry. Learn more: https://bit.ly/3V9JmAR   #BIO2024

#BIO2024 is almost here! We look forward to gathering with the broader life sciences community where business and breakthroughs converge at the world’s largest #biotech gathering June 3-6 in San Diego, CA.    Want to connect on-site? Send us a meeting request in the BIO partnering system: https://bit.ly/4dG5E4i

This week, Paul-Joseph (PJ) Aspuria, Ph.D., Senior Director, Cell Therapy, and Sandro Vivona, Ph.D., Senior Director, Biochemistry and BioPhysics will present on our innovative cytokine engineering technologies at the PEGS Boston Summit 2024.    Learn more: https://lnkd.in/gTvzac3Q   https://lnkd.in/gJXzsXYj   #PEGS2024

As champions in innovation, we understand the importance of environmental stewardship in everything we do. Today, on #EarthDay, we reiterate our commitment to making a positive impact on the environment, from reducing our ecological footprint to promoting eco-friendly practices throughout our operations. Discover how we take meaningful action to protect our environment and promote a healthier future for all, below:

#ICYMI Our CEO, Debanjan Ray, sat down with Annalee Armstrong of Fierce Biotech to discuss the positive initial results from our Phase 1a/1b clinical trial of STK-012, a first-in-class α/β-biased IL-2 partial agonist for the treatment of advanced solid tumors presented at the 2024 American Association for Cancer Research Annual Meeting.    Check out the full article for more on these exciting results and how we are leveraging the transformative potential of IL-2 to revolutionize the treatment paradigm for #cancer patients: https://bit.ly/49vYvAf   #AACR24 #CytokineScience

#ICYMI Last week, we presented preclinical data on our orthoIL-2 technology at the American Association for Cancer Research Annual Meeting. In comparison to other armoring approaches for CAR T-cell therapy, this study demonstrated superior anti-tumor activity and safety with our orthoIL-2 technology. These data provide novel insights on the potential of orthoIL-2 signaling to selectively enhance and sustain a favorable effector state of CAR T-cells. Learn more and see the full poster here: https://bit.ly/4aJP5SO   #AACR24 #CytokineScience

Today, we presented positive initial results from our Phase 1a/1b clinical trial of STK-012, a first-in-class α/β-biased IL-2 partial agonist for the treatment of advanced solid tumors, at the 2024 American Association for Cancer Research Annual Meeting. Data highlights include a favorable tolerability profile without severe toxicities typically associated with IL-2 treatments and multiple objective responses from STK-012 monotherapy. Learn more about our exciting results: https://bit.ly/49qBCy9   #AACR24 #CytokineScience